Cambridge, MA, United States
Cambridge, MA, United States

Time filter

Source Type

ReportsnReports.com adds "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2016" to its store providing comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Complete report on H2 2016 pipeline review of Chronic Obstructive Pulmonary Disease (COPD) with 172 market data tables and 16 figures, spread across 577 pages is available at http://www.reportsnreports.com/reports/743409-chronic-obstructive-pulmonary-disease-copd-pipeline-review-h2-2016.html . Companies discussed in this Chronic Obstructive Pulmonary Disease (COPD) Pipeline Review, H2 2016 report include AB2 Bio Ltd., Abeona Therapeutics, Inc., Ache Laboratorios Farmaceuticos S/A, Achillion Pharmaceuticals, Inc., Adamis Pharmaceuticals Corporation, Advinus Therapeutics Ltd, AlgiPharma AS, Allinky Biopharma, Alteogen Inc., Amakem NV, Ampio Pharmaceuticals, Inc., Angion Biomedica Corp., Apellis Pharmaceuticals Inc, Aridis Pharmaceuticals LLC, Astellas Pharma Inc., AstraZeneca Plc, Asubio Pharma Co., Ltd., Axikin Pharmaceuticals, Inc., Bayer AG, Beech Tree Labs, Inc., Bioneer Corporation, Biotie Therapies Corp., Boehringer Ingelheim GmbH, C4X Discovery Holdings PLC, Carolus Therapeutics, Inc., Cellular Biomedicine Group, Inc., Chiesi Farmaceutici SpA, Circassia Pharmaceuticals Plc, CSL Limited, Cytokinetics, Inc., Daiichi Sankyo Company, Limited, Diffusion Pharmaceuticals Inc., Domainex Limited, Elsalys Biotech SAS, enGene, Inc, Errant Gene Therapeutics, LLC, F. Hoffmann-La Roche Ltd., Foresee Pharmaceuticals, LLC, Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline Plc, Hanmi Pharmaceuticals, Co. Ltd., iCeutica, Inc., InMed Pharmaceuticals Inc., Innate Pharma S.A., INVENT Pharmaceuticals, Inc., Invion Limited, Jiangsu Hansoh Pharmaceutical Co., Ltd., Johnson & Johnson, KaloBios Pharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Ligand Pharmaceuticals, Inc., Medestea Research & Production S.p.A., Merck & Co., Inc., Mereo Biopharma Group Plc, Meridigen Biotech Co., Ltd., Microbion Corporation, Novartis AG, Odan Laboratories Ltd., OPKO Health, Inc., Orion Oyj, Panmira Pharmaceuticals, LLC., Pfizer Inc., PharmaLundensis AB, Pharmaxis Limited, Pila Pharma AB, Polyphor Ltd., Promedior, Inc., ProMetic Life Sciences Inc., Proteostasis Therapeutics, Inc., Pulmagen Therapeutics LLP, Pulmatrix, Inc., Quark Pharmaceuticals, Inc., Re-Pharm Limited, Recipharm AB, Respira Therapeutics Inc, Respiratorius AB, rEVO Biologics, Inc., Rhizen Pharmaceuticals S.A., SATT North SAS, Selvita S.A., Seoul Pharma Co., Ltd., Spring Bank Pharmaceuticals, Inc., Stelic Institute & Co., Inc., sterna biologicals Gmbh & Co KG, Sucampo Pharmaceuticals, Inc., Sun Pharma Advanced Research Company Ltd., Sunovion Pharmaceuticals Inc., Synovo GmbH, Syntrix Biosystems, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., TGV-Laboratories, Therabron Therapeutics, Inc., Theravance Biopharma, Inc., Torrent Pharmaceuticals Limited, U.S. Stem Cell, Inc., Unizyme Laboratories A/S, Vectura Group Plc, Verona Pharma Plc, Vertex Pharmaceuticals Incorporated, Yuhan Corporation, Yungjin Pharm. Co., Ltd. and Zambon Company S.p.A. The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 1, 13, 40, 29, 81, 25 and 5 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively for Chronic Obstructive Pulmonary Disease (COPD). Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Connect With Us on:


The International Association of HealthCare Professionals is pleased to welcome Majd Mouded, MD, Pulmonologist to their prestigious organization with his upcoming publication in The Leading Physicians of the World. Dr. Majd Mouded is a highly trained and qualified physician with an extensive expertise in all facets of his work. Dr. Mouded has been in practice for 17 years and is currently serving as Medical Director within Proteostasis Therapeutics Inc. in Cambridge, Massachusetts. Dr. Mouded attended Tufts University School of Medicine in Boston, Massachusetts, graduating with his Medical Degree in 1999. He subsequently completed his residency at Johns Hopkins Hospital Osler Medical Residency Program, before undertaking his Pulmonary and Critical Care Medicine fellowship training at the Harvard Combined Program, Beth Israel Deaconess Medical Center, Brigham & Women’s Hospital, and Massachusetts General Hospital. Dr. Mouded is a board certified physician in Pulmonary and Critical Care Medicine by the American Board of Internal Medicine. In addition, Dr. Mouded serves as Adjunct Professor of Medicine at the University of Pittsburgh Medical School, and Clinical Instructor of Medicine and Harvard Medical School. He maintains professional memberships with the American Thoracic Society and the American College of Chest Physicians, allowing him to stay current on the latest advances in his field. For his wealth of experience and knowledge, Dr. Mouded is the recipient of several awards and recognitions, and has been published extensively. Learn more about Dr. Mouded by reading his upcoming publication in The Leading Physicians of the World. FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics.  Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review.  FindaTopDoc.com features each doctor’s full professional biography highlighting their achievements, experience, patient reviews and areas of expertise.  A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life.  For more information about FindaTopDoc, visit http://www.findatopdoc.com


News Article | November 10, 2016
Site: globenewswire.com

CAMBRIDGE, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis, today reported financial results for the third quarter ended September 30, 2016. Revenue was $1.7 million for the three months ended September 30, 2016, compared to $1.2 million for the three months ended September 30, 2015. The increase was the result of an increase in revenue recognized from the Company’s collaboration with Astellas. Research and development expenses were $9.2 million for the three months ended September 30, 2016, compared to $6.3 million for the three months ended September 30, 2015. The increase was primarily due to an increase of $2.6 million related to activities supporting the Company’s Phase 1 clinical trials of PTI-428 which commenced during the first quarter of 2016. General and administrative expenses were $3.3 million for the three months ended September 30, 2016, compared to $1.5 million for the three months ended September 30, 2015. The increase was primarily due to a $0.8 million increase in personnel-related costs, a $0.6 million increase in professional fees and a $0.3 million increase in occupancy and other facility-related costs. Net loss was $10.8 million for the three months ended September 30, 2016, compared to $7.1 million for the three months ended September 30, 2015. The increase in net loss was primarily attributable to the increase in operating expenses noted above. Cash, cash equivalents and short-term investments were $100.2 million as of September 30, 2016, including the proceeds from the Company’s follow-on public offering in the third quarter of 2016. In September 2016, the Company closed its follow-on public offering of 5,750,000 shares of its common stock at a public offering price of $13.00 per share. The net proceeds from the offering were $69.5 million, after deducting the underwriting discount and expenses associated with the offering payable by the Company. Based on the Company’s current operating plan, the Company expects its cash, cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditures requirements through the second quarter of 2018. Proteostasis Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery of groundbreaking therapies to treat diseases caused by dysfunctional protein processing, such as cystic fibrosis (CF). Headquartered in Cambridge, MA, the Proteostasis Therapeutics team focuses on identifying therapies that modulate the proteostasis imbalance in cells and restore protein function. Proteostasis Therapeutics is currently enrolling eligible adults with CF to participate in its Phase 1 clinical trials of PTI-428. In addition to its multiple programs in cystic fibrosis, Proteostasis Therapeutics has formed collaborations with Biogen to research and identify therapeutic candidates for neurodegenerative disease and with Astellas Pharma, Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway. For more information, visit www.proteostasis.com. Safe Harbor To the extent that statements in this release are not historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.  Examples of forward-looking statements made in this release include, without limitation, statements regarding the sufficiency of our cash balances to fund our operating and capital expenses through an expected date.  Forward-looking statements made in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved.  Such risks and uncertainties include, without limitation, uncertainties inherent in the execution and completion of clinical trials, in the timing of availability of trial data, in the actions of regulatory agencies, and those set forth in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, and our other SEC filings.  We assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Loading Proteostasis Therapeutics collaborators
Loading Proteostasis Therapeutics collaborators